Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.07 +0.15 (+0.60%)
Official Closing Price Updated: 7:00 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing. 
Via Benzinga
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population
Via Stocktwits
Smart Money Is Betting Big In PFE Options
 
Via Benzinga
Price Over Earnings Overview: Pfizer
 
Via Benzinga
This Is What Whales Are Betting On Pfizer
 
Via Benzinga
RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.
Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday. 
Via Investor's Business Daily
Unusual Put Option Activity In Pfizer Stock - Have Investors Turned Bearish?
PFE stock still looks cheap today. This is from a historical value standpoint and using analysts' and management's projections. 
Via Talk Markets
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
Robert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk Groups
Moderna’s Covid vaccine has been authorized for individuals six months and older, Pfizer's for ages five and up, and Novavax's for ages 12 and above. 
Via Stocktwits
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
My 3 Favorite Stocks to Buy Right Now
Contrary to a common assumption at this time, not every stock is priced too richly or poses too much risk. Several underappreciated and undervalued names are just waiting to be found. 
Via The Motley Fool
EU Rushes To Scrap Tariffs On US Goods To Unlock Lower American Auto Duties: These Exporters Stand To Gain Big
EU set to scrap tariffs on U.S. goods in a key auto trade deal. See which American industrial and energy stocks are poised for a boost. 
Via Benzinga
Topics World Trade
The New Iron Curtain: Tariffs Reshape Global Economy, Sparking Uncertainty and Inflation
The global economic landscape is currently undergoing a seismic shift, as the United States has aggressively implemented a series of new tariffs and trade policy changes throughout 2025. These actions... 
Via MarketMinute
Topics Bonds Economy Government
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic. 
Via Benzinga
Topics Government
When AI Execs Say the Market Looks Bubbly
Market chatter about the frothiness of the AI market seems to be picking up as OpenAI CEO Sam Altman claims that he too sees a bubble forming. 
Via The Motley Fool
Topics Artificial Intelligence
Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts
Powell’s dovish Jackson Hole remarks signal that the Fed could cut rates as early as September, with markets now pricing an 80% chance of a 25 bps cut. 
Via MarketBeat
Topics ETFs Economy
3 Stocks Under $50 Walking a Fine Line
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Topics Artificial Intelligence
2 Reasons to Watch ZTS and 1 to Stay Cautious
Over the past six months, Zoetis’s shares (currently trading at $156.80) have posted a disappointing 7% loss, well below the S&P 500’s 8.6% gain. This might have investors contemplating their next... 
Via StockStory
Topics Government Stocks World Trade
The "Ten Titans" Stocks Now Make Up 38% of the S&P 500. Here's What It Means for Your Investment Portfolio
Massive growth stocks are driving the performance of the S&P 500, for better or for worse. 
Via The Motley Fool
Topics Economy Stocks
3 Unstoppable Dividend Stocks to Buy Right Now
Investors will get great dividends and more with these stocks. 
Via The Motley Fool
Topics World Trade
My 5 Favorite Stocks to Buy Right Now
Not every ticker worth owning at this time has raced to an uncomfortably high price. 
Via The Motley Fool
Topics Artificial Intelligence
Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years
HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market. 
Via Benzinga
Looking for the most active stocks in the S&P500 index on Thursday?
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
My Top Dividend-Paying, Deep-Value Stock to Buy in August
You won't find many stocks with a juicier dividend and more attractive valuation than this big pharma stock. 
Via The Motley Fool
Topics Earnings Intellectual Property
2 S&P 500 Stocks to Own for Decades and 1 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend $40 Billion+ Market
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback